Champions Oncology, Inc.

Upcoming Webinar! 🔬 Targeting KRAS Mutations: Latest Therapeutic Approaches and Clinical Insights KRAS-directed therapy is advancing rapidly, with new clinical data accelerating interest in G12C, G12D, G12V, pan-KRAS, and pan-RAS(ON) approaches. Join Amy Wesa and Michael Boice as they explore the evolving KRAS landscape, review key clinical insights across NSCLC, colorectal, and pancreatic cancer, and discuss the combination strategies shaping the next generation of KRAS-targeted drug development. The session will conclude with a live Q&A. 📅 August 27, 2026 ⏰ 4pm GMT | 11am EST | 8am PT 👉 Register now and secure your spot: https://hubs.li/Q04r1v4s0

🔬NEW WHITE PAPER: Seeing Beyond Efficacy: How Radiolabeling De-Risks ADC Development and Accelerates Clinical Success https://lnkd.in/gbWhw_2Q Antibody-drug conjugates (ADCs) are transforming cancer therapy, but their path to the clinic is still filled with uncertainty especially when it comes to biodistribution, target engagement, and payload release. Our latest white paper explores how radiolabeling turns an ADC into its own tracer, revealing where it goes, how it behaves, and what happens to the payload, insights that traditional efficacy studies often miss. • How radiolabeling uncovers off-target risks before IND submission • Why regulatory agencies increasingly expect biodistribution data • Best practices for isotope selection, model design, and study planning • How Champions’ integrated workflow accelerates ADC and radiopharmaceutical programs from idea to data 📘 Download the white paper: https://lnkd.in/gbWhw_2Q From discovery to clinical translation, radiolabeling gives ADC developers the clarity they need to move forward with confidence. #ADCs #Radiopharmaceuticals #OncologyResearch #TranslationalScience #ChampionsOncology

🔬NEW WHITE PAPER: Seeing Beyond Efficacy: How Radiolabeling De-Risks ADC Development and Accelerates Clinical Success https://lnkd.in/gbWhw_2Q Antibody-drug conjugates (ADCs) are transforming cancer therapy, but their path to the clinic is still filled with uncertainty especially when it comes to biodistribution, target engagement, and payload release. Our latest white paper explores how radiolabeling turns an ADC into its own tracer, revealing where it goes, how it behaves, and what happens to the payload, insights that traditional efficacy studies often miss. • How radiolabeling uncovers off-target risks before IND submission • Why regulatory agencies increasingly expect biodistribution data • Best practices for isotope selection, model design, and study planning • How Champions’ integrated workflow accelerates ADC and radiopharmaceutical programs from idea to data 📘 Download the white paper: https://lnkd.in/gbWhw_2Q From discovery to clinical translation, radiolabeling gives ADC developers the clarity they need to move forward with confidence.

Discover how our unique PDX + radiolabeled-compounds platform unlocks precise tumor targeting and heterogeneity insights. For researchers driving innovation in radiopharmaceuticals, precision matters. Champions is the only CRO integrating patient-derived xenograft (PDX) models with radiolabeled compounds, enabling you to interrogate tumor targeting, uptake, and heterogeneity in a clinically relevant setting. Learn more about our PDX-based radiopharma platform: https://lnkd.in/ge7wVSrj

Clinically Relevant Radiopharmaceutical Studies Start with Champions We’ve officially launched a new platform designed to move radiolabeled therapies forward, with the translational confidence your team needs. What makes our approach different? We’ve combined in-house radiochemistry workflows with Champions’ clinically annotated PDX models, giving you access to: 🔬 Radiolabeling with therapeutic isotopes (Lu-177, Ac-225, In-111, Cu-67, Y-90, Pb-212, At-211, Tb-161, Cu-64, Zr-89) 🧪 Stability, binding, internalization & functional assays 🐁 In vivo dosimetry & efficacy in human-relevant models 💡 Access Lumin, our platform of 1400+ well-characterized, clinically relevant PDX tumors Champions is ready to support your next-generation radiopharmaceutical program, from proof of concept through IND. Learn More👉 https://lnkd.in/g76V3fJd #Radiopharmaceuticals #PreclinicalResearch #PDXModels #TargetedTherapies #TranslationalOncology #Biotech #OncologyCRO #Radiochemistry #OncologyInnovation

Test your candidate in models built from actual patient tumors - deliver clinical relevance early. When the success of your radiopharma candidate depends on real-world biology, model choice is everything. Our platform uniquely combines preclinical radiopharmaceutical development with PDX models derived from actual patient tumors, delivering a depth of translational data that cell lines alone cannot match. Explore the Champions radiopharma study platform: https://lnkd.in/gZcP9FA8